x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

WTR Healthcare Happenings

WTR Healthcare Happenings is a weekly conversation with healthcare executives, medical experts, and investors on recent clinical data or industry-driving events in healthcare.

business investing

All Episodes

8:41

Trump's Psychedelic Medicine Executive Order: What It...

WTR Healthcare Happenings ·

2026/04/21

Water Tower Research's healthcare equity analyst Robert Sassoon breaks down President Trump's executive order on therapeutic psychedelics, examining the five key mechanisms it puts in place — from accelerated FDA review vouchers and right-to-try expansion to federal funding and ibogaine pathway clearance. Sassoon explains what the order gets right, where it falls short (namely on reimbursement and rescheduling), and which companies — including Compass Pathways, Dephinium Therapeutics, and Hel...

en-us

5:47

WTR Insights Conference Preview: Nurexone's Nerve...

WTR Healthcare Happenings ·

2026/04/10

In this special preview episode of WTR Healthcare Happenings, Robert Sassoon spotlights two biotechs presenting on Day 1 of the WTR Insights Conference (April 14–15). Nurexone Biologic (TSX-V: NRX | OTCQB: NRXBF) is pioneering an exosome-based therapy for spinal cord injury and other CNS conditions, with Phase 1/2A trials expected to initiate within 12 months. Anixa Biosciences (NASDAQ: ANIX) is advancing a breast cancer vaccine and a novel CAR-T therapy for ovarian cancer — both approaching ...

en-us

23:50

Circular Genomics: Cracking the Brain Code with...

WTR Healthcare Happenings ·

2026/04/01

In this episode of the WTR Healthcare Happenings podcast, Water Tower Research’s Shawn Severson and Robert Sassoon are joined by Dr. Paul Sargeant, President and CEO of Circular Genomics, a privately held molecular diagnostics company developing next‑generation blood tests based on circular RNA biomarkers. The conversation explores the science behind circular RNA, the company’s product pipeline, including the pursuit of an out‑licensing strategy, depression assay strategy, and a planned late-...

en-us

11:55

Unmasking the Treatment Landscape for Obstructive...

WTR Healthcare Happenings ·

2026/03/27

Robert Sassoon, WTR Senior Healthcare Analyst, joins Tim Gerdeman to discuss obstructive sleep apnea (OSA) and the rapidly evolving treatment landscape for this widespread yet often undiagnosed and potentially fatal condition. The conversation explores the shift away from CPAP amid high non‑adherence rates toward emerging alternatives, including neurostimulation, pharmacotherapy, and oral appliances. Sassoon also highlights the valuation gap between incumbents such as ResMed (NYSE: RMD) and i...

en-us

13:28

Psychedelics at a Turning Point: The Trials That...

WTR Healthcare Happenings ·

2026/03/20

Robert Sassoon, WTR Senior Healthcare Analyst, joins Shawn Severson, CEO of WTR, to break down the latest clinical readouts in advanced psychedelics — including Compass Pathways’ Phase III progress in treatment‑resistant depression, new anxiety data from Helis, and the upcoming milestones that could shape the future of mental health treatment. From durability and dosing models to regulatory momentum and investor implications, this episode explores why 2026 may be a pivotal year for the field

en-us

24:26

Anixa Biosciences (ANIX): CEO Dr. Amit Kumar on Why...

WTR Healthcare Happenings ·

2026/03/12

In this episode of the WTR Healthcare Happenings, we welcome back Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: ANIX) who explains why 2026 is shaping up to be a pivotal year for the company. Building on the momentum of 2025, Dr. Kumar walks us through key developments across Anixa’ clinical pipeline and strategic direction. He outlines the company’s plans as its breast cancer vaccine progresses into Phase 2 following strong Phase 1 results. At the same time, he emphasizes th...

en-us

30:17

Omniscient Neurotechnology: Scaling up Clinical...

WTR Healthcare Happenings ·

2026/03/04

In this episode of the WTR Healthcare Happenings, Adam Fraser, COO of Omniscient Neurotechnology—a privately held, Australian‑based but U.S.-focused company pioneering AI‑driven brain mapping—joins Water Tower Research Co‑Founder Tim Gerdeman and Healthcare Analyst Robert Sassoon for a deep dive into the future of clinical connectomics. The discussion explores how Omniscient’s flagship platform, Quicktome, uses advanced AI to transform complex brain data into intuitive, Google‑Maps‑style netw...

en-us

30:01

Decoy Therapeutics (DCOY): CEO Rick Pierce on the...

WTR Healthcare Happenings ·

2026/02/25

In this episode of the WTR Healthcare Happenings podcast, Tim Gerdeman, Vice Chair, Co-Founder, and CMO of Water Tower Research, and Robert Sassoon, WTR’s Healthcare Research Analyst, speak with Rick Pierce, CEO of Decoy Therapeutics (NASDAQ: DCOY). The conversation explores Decoy’s innovative business model for developing peptide‑conjugate antivirals designed to target multiple respiratory viruses. Pierce explains how Decoy is navigating the modern era of drug development with a cost‑effecti...

en-us

33:55

The Medicus Pharma (MDCX) Playbook: De-Risking Drug...

WTR Healthcare Happenings ·

2026/02/18

In this episode of the WTR Healthcare Happenings podcast, Tim Gerdeman, Vice Chair, Co‑Founder, and CMO of Water Tower Research, and Robert Sassoon, WTR’s Healthcare Research Analyst, speak with Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma (NASDAQ: MDCX). Dr. Bokhari outlines Medicus Pharma’s distinctive strategy of acquiring de‑risked, mid‑stage therapeutic assets and advancing them through Phase 2 development to attract major pharmaceutical partners. The discussion centers...

en-us

11:47

CEO Dr. Lior Shaltiel Discusses the Investment Thesis...

WTR Healthcare Happenings ·

2026/02/11

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Dr. Lior Shaltiel, CEO of NuroExone Biologic (OTCQB: NRXBF/TSXV: NRX), an early-stage regenerative therapy developer. The conversation centers on NurExone’ lead product, ExoPTEN, a therapeutic platform that combines exosomes with siRNA to promote nerve regeneration in multi-billion dollar markets like spinal cord and optic nerve injury. Dr. Shaltiel outlines the company’s strong preclinic...

en-us

27:26

Taking Aim at Norovirus; Cocrystal Pharma's (COCP)...

WTR Healthcare Happenings ·

2026/02/04

In this episode of the WTR Healthcare Happenings Podcast, Tim Gerdeman and Robert Sassoon speak with Jim Martin, Co‑CEO and CFO of Cocrystal Pharma (NASDAQ: COCP). Martin explains the company’s Nobel Laureate‑developed drug discovery platform, which uses high-resolution crystallography to target viral regions resistant to mutation, enabling broad‑spectrum antivirals. The discussion highlights Cocrystal’s lead candidate, CDI‑988, a dual‑indication antiviral for coronaviruses and noroviruses, w...

en-us

28:12

How Entropy Neurodynamics (ASX: ENP) Is Shaping...

WTR Healthcare Happenings ·

2026/01/28

In this episode of the WTR Healthcare Happenings Podcast, host Tim Gerdeman and healthcare analyst Robert Sassoon are joined by Dr. Jim Gilligan, President and Chief Science Officer of Entropy Neurodynamics (ASX: ENP), formerly Tryptamine Therapeutics. Dr. Gilligan explains the motivation behind the company’s rebrand and its decision to prioritize three core therapeutic targets: Binge Eating Disorder, Fibromyalgia, and Irritable Bowel Syndrome/abdominal pain. Although Entropy has reported pos...

en-us

13:09

Anixa' (ANIX) T-Cell Innovations Demonstrate Early...

WTR Healthcare Happenings ·

2026/01/22

In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman sits down with WTR Healthcare analyst Robert Sassoon to discuss his Initiation of Coverage Report on Anixa Biosciences. Their conversation explores Anixa’s two clinical‑stage programs—one, an innovative CAR‑T cell therapy for terminal ovarian cancer patients, and the other, a breast cancer vaccine designed for both treatment and prevention. They review Phase 1 results, upcoming 2026 milestones, and how An...

en-us

7:11

The lure of the NASDAQ for Biotechs

WTR Healthcare Happenings ·

2026/01/16

In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman and WTR Healthcare analyst Robert Sassoon break down why more than 90% of biotech companies listed on a U.S. exchange choose NASDAQ over the NYSE.

en-us

18:38

Redefining Cancer Treatment: Calidi Biotherapeutics’...

WTR Healthcare Happenings ·

2026/01/08

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Eric Poma PhD, CEO of Calidi Biotherapeutics Inc (NYSE American: CLDI). The discussion focuses on how Calidi is solving the "delivery problem" in cancer treatment, and specifically how to transport cancer-killing oncolytic viruses systemically through the bloodstream without the body’s immune system neutralizing them before they reach the tumor.

en-us

19:47

Co-Diagnostic' Technology to Deliver Accessible,...

WTR Healthcare Happenings ·

2025/12/23

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Dwight Egan, CEO of Co-Diagnostics Inc. (NASDAQ: CODX), about the company’s evolution from a pandemic-era PCR testing provider to a diversified molecular diagnostics leader. In our discussion, Egan highlights the Co-DX PCR Pro, a portable, cost-effective device that delivers gold-standard PCR testing outside the lab and explains how its patented Co-Primer multiplexing technology sets it apart...

en-us

22:05

CEO Jagi Gill on How Apyron' Innovative...

WTR Healthcare Happenings ·

2025/12/19

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon talk with Apyron CEO Jagi Gill about the company's innovative neurostimulation technology for chronic pain, an all too prevalent affliction affecting millions of people. Gill explains why Apyron’s patient-focused approach stands out, and outlines the market opportunity and commercialization strategy.

en-us

16:28

RenovoRx’ Differentiated Targeted Drug Delivery...

WTR Healthcare Happenings ·

2025/12/18

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Shaun Bagai, CEO of RenovoRx (NASDAQ: RNXT). The company is pioneering targeted oncology therapies and commercializing RenovoCath™, an FDA-cleared multi-specialty local drug delivery device for high unmet needs. We discuss the innovation and advantages of its TAMP™ (Trans-Arterial Micro-Perfusion) platform—powered by the proprietary dual-balloon catheter—and how it sets RenovoRx apart in trea...

en-us

11:03

Vivos Therapeutics’ Mission to Transform Sleep...

WTR Healthcare Happenings ·

2025/12/10

In this WTR Healthcare Happenings Spotlight Flashcast, host Tim Gerdeman sits down with WTR's Healthcare Analyst Robert Sassoon to discuss his recently published initiation of coverage on Vivos Therapeutics (NASDAQ: VVOS). The conversation explores Vivos’ innovative approach to treating obstructive sleep apnea (OSA), the company's transformative shift to a vertically integrated, patient-centric business model, and the significant market opportunity ahead. Tune in for insights on growth strate...

en-us

11:46

GenSight Biologics' Novel Gene Therapy Approach to...

WTR Healthcare Happenings ·

2025/12/03

On the latest WTR Healthcare Happenings podcast episode, we welcomed Jan Eryk Umiastowski, CFO of GenSight Biologics (Euronext Paris: SIGHT), a late clinical-stage biopharma company based in Paris, France, primarily focused on developing and commercializing novel disease-modifying gene therapies aimed at reversing vision loss from severe neurodegenerative retinal diseases. He discusses GenSight's development pipeline, what's unique about the company's approach to gene therapy and upcomi...

en-us

48 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...